Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups

Saved in:
Bibliographic Details
Published in:Current controlled trials in cardiovascular medicine 2011-12, Vol.12 (S1), p.A88-A88, Article A88
Main Authors: A’Hern, Roger, DeBono, Johann, Sandhu, Shahneen, Kalaitzaki, Eletheria, Usdin, Martine, Hall, Emma E
Format: Article
Language:English
Subjects:
Biomarkers
Oral Presentation
Patients
Prostate cancer
Response rates
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1745-6215
1745-6215
DOI:10.1186/1745-6215-12-S1-A88